Any current/future new fundraising through debt or equity?

The company currently has no long-term debt and is essentially debt-free except for some pre-shipment facility at low interest (3% to 3.1%). There is no mention of any current or future fundraising plans through equity or debt in the transcript. The company is focusing on internal accruals for funding, including CAPEX of around Rs. 4 crores for capacity expansion. No plans to associate with any Investor Relations (IR) firm for fundraising are indicated. Overall, the company appears financially stable with no immediate plan for raising funds via debt or equity.

Any current/future capex/capital investment/strategic investment?

The company plans to invest an additional ₹4 crores in CAPEX during the current financial year (2021-2022). This investment aims to increase manufacturing capacity from 1,200 metric tons to 1,500 metric tons by 31st March 2022. The expansion involves adding a few equipment and machinery to the existing setup; most infrastructure is ready. The company is actively exploring inorganic expansion opportunities but is waiting for the right candidate or proposal. They welcome acquisition proposals monthly and will proceed when a suitable target is identified. The focus is also on backward integration

Future growth expectations in sales/revenue/volumes?

The company expects approximately 30% growth in top line and bottom line for FY22, targeting revenue between Rs. 480 to 500 crores. Current order book as of 1st July 2021 is Rs. 90 crores, indicating good demand. Q2, Q3, and Q4 sales growth is expected to be similar, driven by conventional products Erythromycin and Pyrazinamide. New products like Gliclazide are contributing and expected to continue providing higher gross margins. Capacity utilization stands at 71%, with plans to expand manufacturing capacity from 1,200 to 1,500 metric tons by March 2022, supporting volume growth. The

Future growth expectations in earnings/operating earnings/profits/EPS?

Anuh Pharma expects around 30% growth in both top line and bottom line for FY22, targeting revenues between ₹480 to ₹500 crores. EBITDA margins are projected to be between 13% to 15%. Profit before tax margins are expected in the range of 8% to 10%, improving with increasing sales in regulated markets. Order book as of July 1, 2021, stands at ₹90 crores, indicating strong demand and visibility for growth. New products like Gliclazide, Ambroxol, Azithromycin, Sulfadoxine contribute to higher margins and sales. Resolution of raw material procurement issues, especially local sourcing re

Current/ Expected Orderbook/ Pending Orders?

The order book position as of 1st July 2021 is ₹90 crore. The company is confident of achieving its top-line and bottom-line targets for the financial year 2022. There is a pending order status as of 1st July 2021, with good sales of products like Gliclazide, Ambroxol, Azithromycin, and Sulfadoxine. Some conventional products like Erythromycin and Pyrazinamide had reduced sales due to COVID-19 but are expected to improve. Raw material procurement issues for one intermediate from China are being resolved with local sourcing expected within 2-3 months to avoid any sales disruptions. Overall, the

Anuh Pharma LtdQ1 FY22Pharmaceuticals & Biotechnology

Anuh Pharma Ltd Q1 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹87.31P/E: 19.8Market Cap: ₹875 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

The company expects approximately 30% growth in top line and bottom line for FY22, targeting revenue between Rs. 480 to 500 crores.
Current order book as of 1st July 2021 is Rs. 90 crores, indicating good demand.
Q2, Q3, and Q4 sales growth is expected to be similar, driven by conventional products Erythromycin and Pyrazinamide.
New products like Gliclazide are contributing and expected to continue providing higher gross margins.
Capacity utilization stands at 71%, with plans to expand manufacturing capacity from 1,200 to 1,500 metric tons by March 2022, supporting volume growth.
The company is resolving raw material procurement constraints to sustain and improve production and sales.
Regulated market sales contribution is expected to increase, with roughly 10% of the top line potentially coming from the USA by 2025.
New commercial projects with product backward integration (e.g., Azithromycin) nearing completion, expected to add revenue.

Margin guidance

Category 3

Anuh Pharma expects around 30% growth in both top line and bottom line for FY22, targeting revenues between ₹480 to ₹500 crores.
EBITDA margins are projected to be between 13% to 15%.
Profit before tax margins are expected in the range of 8% to 10%, improving with increasing sales in regulated markets.
Order book as of July 1, 2021, stands at ₹90 crores, indicating strong demand and visibility for growth.
New products like Gliclazide, Ambroxol, Azithromycin, Sulfadoxine contribute to higher margins and sales.
Resolution of raw material procurement issues, especially local sourcing replacing Chinese imports, is expected to support margin recovery.
The company foresees steady capacity utilization improvements with planned capex increasing manufacturing capacity from 1,200 to 1,500 metric tons by March 2022.
By 2025, expects at least 10% of revenues from the US regulated market, supporting higher realizations and profits.

See what Anuh Pharma Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

The company currently has no long-term debt and is essentially debt-free except for some pre-shipment facility at low interest (3% to 3.1%).
There is no mention of any current or future fundraising plans through equity or debt in the transcript.
The company is focusing on internal accruals for funding, including CAPEX of around Rs. 4 crores for capacity expansion.
No plans to associate with any Investor Relations (IR) firm for fundraising are indicated.
Overall, the company appears financially stable with no immediate plan for raising funds via debt or equity.

Order book

Yes

The order book position as of 1st July 2021 is ₹90 crore.
The company is confident of achieving its top-line and bottom-line targets for the financial year 2022.
There is a pending order status as of 1st July 2021, with good sales of products like Gliclazide, Ambroxol, Azithromycin, and Sulfadoxine.
Some conventional products like Erythromycin and Pyrazinamide had reduced sales due to COVID-19 but are expected to improve.
Raw material procurement issues for one intermediate from China are being resolved with local sourcing expected within 2-3 months to avoid any sales disruptions.
Overall, the company expects similar or continued growth in upcoming quarters (Q2, Q3, and Q4) supported by a current strong order book and resolution of raw material constraints.

See what Anuh Pharma Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

The company plans to invest an additional ₹4 crores in CAPEX during the current financial year (2021-2022).
This investment aims to increase manufacturing capacity from 1,200 metric tons to 1,500 metric tons by 31st March 2022.
The expansion involves adding a few equipment and machinery to the existing setup; most infrastructure is ready.
The company is actively exploring inorganic expansion opportunities but is waiting for the right candidate or proposal.
They welcome acquisition proposals monthly and will proceed when a suitable target is identified.
The focus is also on backward integration in production, such as making Azithromycin from earlier stages, to reduce dependence on Chinese imports and improve margins.

Track Anuh Pharma Ltd — get its next earnings analysis in your feed

How does Anuh Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisAnuh Pharma Ltd

Rev 2Mar 3

See where Anuh Pharma Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Anuh Pharma Ltd rank in Pharmaceuticals & Biotechnology?

Compare Anuh Pharma Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY22) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Anuh Pharma Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Accretion Pharmaceuticals Ltd (Q2 FY27)
25.85% increase) . Key results statement takeaways from Accretion Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Sigachi Industries Ltd (Q2 FY27)
Year-on-Year (YoY) Revenue Growth: 18.09% (Q2 FY27 vs Q2 FY26) . Key investor presentation takeaways from Sigachi Industries Ltd's Q2 FY27 investor presentation
Advanced Enzyme Technologies Ltd (Q2 FY27)
Q2 FY27 revenue from operations: ₹2,145 million, up 16% YoY from ₹1,845 million in Q2 FY26 (Page 13, 5). Key investor presentation takeaways from Advanced Enzym
IOL Chemicals (Q2 FY27)
Q2 FY27 revenue from operations: ₹795.0 Cr, a 40.1% year-on-year (YoY) increase from ₹567.5 Cr in Q2 FY26 (Page 7). Key investor presentation takeaways from IOL

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →